Curated News
By: NewsRamp Editorial Staff
September 10, 2025
Quantum BioPharma Gets BUY Rating, $45 Target from Kingswood
TLDR
- Quantum BioPharma's BUY rating and $45 target offer investors potential gains from its Lucid-MS drug advancing through clinical trials toward 2029 launch.
- Kingswood's $45 valuation for Quantum BioPharma is based on discounted cash flow analysis assuming successful Phase 2/3 trials from 2026-2028 and commercial launch in 2029.
- Quantum BioPharma's treatments for neurodegenerative and alcohol misuse disorders could significantly improve patient lives and advance medical science for challenging conditions.
- Quantum BioPharma's Lucid-MS compound shows promise in reversing myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Impact - Why it Matters
This development matters because positive analyst coverage from reputable firms like Kingswood Capital can significantly influence investor confidence and stock performance for emerging biotech companies. For patients suffering from neurodegenerative disorders like multiple sclerosis, Quantum BioPharma's lead candidate Lucid-MS represents potential hope for treatments that address the root cause of myelin degradation rather than just symptoms. The biopharmaceutical sector is highly competitive and capital-intensive, making independent validation crucial for attracting further investment to advance clinical trials and ultimately bring innovative therapies to market that could improve quality of life for millions affected by these conditions.
Summary
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, has received a significant vote of confidence from Kingswood Capital Partners. The investment firm initiated coverage with a BUY rating and a substantial US$45 price target, based on a discounted cash flow analysis that anticipates successful Phase 2 and 3 trials of their lead candidate Lucid-MS between 2026 and 2028, followed by a commercial launch in 2029. The coverage report, led by Kingswood Senior Equity Analyst Karen Sterling, PhD, CFA, was prepared independently without compensation from Quantum BioPharma, lending credibility to the optimistic assessment.
The company's flagship product, Lucid-MS, is a patented new chemical entity that has shown promise in preclinical models by preventing and reversing myelin degradation—the underlying mechanism of multiple sclerosis. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is advancing this innovative treatment. Additionally, the company maintains strategic investments via FSD Strategic Investments Inc. and holds a 20.11% stake in Unbuzzd Wellness Inc., which markets the OTC version of unbuzzd™, with Quantum retaining rights to develop pharmaceutical versions. The full press release detailing this coverage initiation is available through the InvestorBrandNetwork, which provides comprehensive corporate communications solutions and press release syndication as part of the Dynamic Brand Portfolio.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Gets BUY Rating, $45 Target from Kingswood
